JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB205333

FITC Anti-Podoplanin antibody [18H5]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal Podoplanin antibody 18H5. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication.

View Alternative Names

GP36, PSEC0003, PSEC0025, PDPN, Podoplanin, Aggrus, Glycoprotein 36, PA2.26 antigen, T1-alpha, Gp36, T1A

2 Images
Flow Cytometry - FITC Anti-Podoplanin antibody [18H5] (AB205333)
  • Flow Cyt

Supplier Data

Flow Cytometry - FITC Anti-Podoplanin antibody [18H5] (AB205333)

Flow cytometric analysis of primary Human dermal lymphatic endothelial cells (HDLEC) labeling Podoplanin with ab205333 at 0.5 μg in 100 μl dilution (lower panel) compared to negative control cells containing no primary antibody (upper panel) or conjugated secondary antibody alone (middle panel).

Flow Cytometry - FITC Anti-Podoplanin antibody [18H5] (AB205333)
  • Flow Cyt

Supplier Data

Flow Cytometry - FITC Anti-Podoplanin antibody [18H5] (AB205333)

Flow cytometric analysis of primary Human dermal lymphatic endothelial cells (HDLEC) labeling Podoplanin with ab205333 at 0.5 μg in 100 μl dilution.

  • Carrier free

    Anti-Podoplanin antibody [18H5] - BSA and Azide free

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

18H5

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>The suggested use of the antibody is &le; 0.5 μg in 100 μl volume. It is recommended that the conjugate antibody should be titrated for optimal performance for each application.</p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
purified from cell culture supernatant
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Podoplanin also known as gp36 and PDPN is a small transmembrane protein weighing approximately 36 kDa. It mainly expresses in lymphatic endothelial cells podocytes and various other tissues like the lung and kidney. It functions as a marker in mesothelial cells and is noticeable in histochemical studies such as mesothelioma using podoplanin staining in immunohistochemistry (IHC). Podoplanin emerges as an important tool in identifying lymphatic vessels and has significant roles in the development of certain tissues.
Biological function summary

The protein participates in maintaining the integrity of cell structures and lymphangiogenesis. This protein does not form part of a larger complex but actively interacts with different molecules. In lymphoid tissues podoplanin contributes to the proper formation of lymphatic channels and assists in platelet aggregation. These actions are pivotal in wound healing and protecting the epithelial cell layers in multiple organs.

Pathways

Podoplanin impacts the platelet activation pathway and the Lymphatic Vessel Development pathway. Its interaction with CLEC-2 (C-type lectin-like receptor 2) triggers downstream signaling leading to changes in platelet morphology and actin cytoskeleton reorganization. Podoplanin’s activation of these pathways links it to key processes that include cell migration and tissue homeostasis TGF-beta interaction also represents a significant relationship within these pathways.

Podoplanin has correlations with conditions like cancer specifically mesothelioma and squamous cell carcinoma. Dysregulation of podoplanin and its pathways may contribute to tumor progression and metastasis. In mesothelioma podoplanin interacts with other proteins like E-cadherin influencing cancer cell migration and adhesion. Its role in disease states highlights the importance of podoplanin IHC as a diagnostic tool aiding in the better understanding and identification of disease pathology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed : 14522983, PubMed : 15231832, PubMed : 17222411, PubMed : 17616532, PubMed : 18215137). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed : 18541721). Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed : 17046996, PubMed : 21376833). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed : 20962267). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate in connection of the lymphatic endothelium to the surrounding extracellular matrix (PubMed : 19268462). In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion (PubMed : 15515019). Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1 (PubMed : 25486435). Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels (PubMed : 9651190). Does not have any effect on folic acid or amino acid transport (By similarity).
See full target information PDPN

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Nanoscale research letters 14:228 PubMed31289961

2019

A Dual Targeting Magnetic Nanoparticle for Human Cancer Detection.

Applications

Unspecified application

Species

Unspecified reactive species

Siwen Wu,Xiyu Liu,Jian He,Huiling Wang,Yiqun Luo,Wenlin Gong,Yanmei Li,Yong Huang,Liping Zhong,Yongxiang Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com